Good Pharmacovigilance Practice (GVP) defines the processes and standards used to detect, evaluate, understand, and prevent adverse effects related to medicinal products.
In clinical trials, GVP-aligned systems support adverse event case processing, medical review, signal detection, and timely safety reporting to regulators and oversight bodies. Strong pharmacovigilance reduces risk by identifying emerging safety issues early and informing risk mitigation actions. GVP also supports consistent safety narratives across development programs and product lifecycle stages. Effective implementation strengthens participant protection and enhances the credibility of safety conclusions.